BiomX (PHGE) News Today → Look what happened to Netflix during these “Hotspot Dates” (From The TradingPub) (Ad) Free PHGE Stock Alerts $0.40 +0.06 (+15.71%) (As of 02:16 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 6:54 AM | msn.comLaidlaw & Co. Initiates Coverage of BiomX (PHGE) with Buy RecommendationMay 22, 2024 | markets.businessinsider.comBiomX Buy Rating Affirmed on Clinical Progress and Strategic AcquisitionMay 22, 2024 | msn.comBiomX Inc. (AMEX:PHGE) Q1 2024 Earnings Call TranscriptMay 21, 2024 | markets.businessinsider.comBiomX’s Strategic Progress and Positive Trials Fuel Buy RatingApril 5, 2024 | seekingalpha.comBiomX Inc. (PHGE) Q4 2023 Earnings Call TranscriptApril 4, 2024 | msn.comBiomX Inc. (AMEX:PHGE) Q4 2023 Earnings Call TranscriptApril 4, 2024 | markets.businessinsider.comBiomX’s Robust Financial Health and Promising Clinical Advancements Bolster Buy RatingFebruary 14, 2024 | msn.comAzitra stock slides on pricing stock offering to raise $5 millionNovember 30, 2023 | finance.yahoo.comBiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023November 29, 2023 | benzinga.comWhy Is Bacterial Infection-Focused BiomX Stock Trading Lower Today?November 29, 2023 | msn.comBiomX mulls pivotal trial for antibacterial after Phase 1/2 data in cystic fibrosisNovember 29, 2023 | markets.businessinsider.comBiomX Announces Positive Results From Phase 1b/2a Study Of BX004 In Chronic Pulmonary InfectionsNovember 23, 2023 | seekingalpha.comBiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any DayNovember 16, 2023 | markets.businessinsider.comPromising Clinical Trials and Financial Stability Bolster BiomX’s Buy Rating: An Analysis by Michael HigginsNovember 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BiomX (PHGE), Quoin Pharmaceuticals (QNRX) and Precigen (PGEN)October 27, 2023 | finance.yahoo.comBiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis ConferenceOctober 18, 2023 | finance.yahoo.comBiomX Announces the Appointment of Edward L. Williams to its Board of DirectorsOctober 4, 2023 | finance.yahoo.comBiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic FibrosisSeptember 7, 2023 | finance.yahoo.comBiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023September 6, 2023 | finance.yahoo.comBiomX to Present at H.C. Wainwright 25th Annual Global Investment ConferenceAugust 9, 2023 | finance.yahoo.comBiomX Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 3, 2023 | finance.yahoo.comBiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023June 8, 2023 | finance.yahoo.comNYSE American Initiates Delisting Proceedings for BiomX WarrantsMay 15, 2023 | finance.yahoo.comBiomX Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 12, 2023 | finance.yahoo.comBiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of DirectorsMay 5, 2023 | finance.yahoo.comBiomX Announces Second Closing of $7.5 Million Private PlacementMarch 27, 2023 | finance.yahoo.comBiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023February 24, 2023 | msn.comWhy Is BiomX (PHGE) Stock Down 18% Today?January 28, 2023 | msn.comBrandon Toranzo Stands Atop Essex CountyJanuary 17, 2023 | marketwatch.comPhage Therapy Market 2023 Expected to Reach Significant Rate by 2028January 12, 2023 | marketwatch.comBacteriophage Market 2023 : Industry Scenario, Strategies, Growth Factors and Forecast to 2028January 12, 2023 | bizjournals.comMd. biotech Adaptive Phage Therapeutics advances fight to wipe out superbugs in cystic fibrosisDecember 19, 2022 | msn.comWhy Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day SessionDecember 18, 2022 | msn.comFull Spectrum hosts gala to raise money for LGBTQ centerNovember 29, 2022 | finance.yahoo.comBiomX To Present at H.C. Wainwright 1st Annual Investor Conference on BacteriophageNovember 12, 2022 | seekingalpha.comBiomX, Inc. (PHGE) Q3 2022 Earnings Call TranscriptNovember 9, 2022 | finance.yahoo.comBiomX Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 2, 2022 | finance.yahoo.comBiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022October 26, 2022 | msn.comZuckerberg is all in on the metaverse whether you like it or notOctober 6, 2022 | msn.comWhy Nauticus Robotics Shares Are Trading Higher By 96%; Here Are 67 Biggest Movers From YesterdaySeptember 14, 2022 | msn.comPackers-Bears home opener weekend is stacked with Luke Combs, Train concerts, Oktoberfest at the Lorelei, igNight Market and pregame partiesSeptember 11, 2022 | finance.yahoo.comBiomX To Present at H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 8, 2022 | finance.yahoo.comBiomX Inc. (PHGE)September 2, 2022 | nasdaq.comBiomX To Report First Part Of CF Trial Data In SeptemberAugust 10, 2022 | finance.yahoo.comBiomX Reports Second Quarter 2022 Financial Results and Provides Business UpdateAugust 4, 2022 | finance.yahoo.comBiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel DiseaseJuly 29, 2022 | msn.comShort Volatility Alert: BiomX Inc.July 9, 2022 | marketwatch.comMicrobiome Therapeutics Market Analysis By Industry Size, Share, Revenue Growth, Development And Demand Forecast To 2029July 6, 2022 | nasdaq.comBiomX To Delist Its Shares From Trading On Tel Aviv Stock ExchangeJuly 6, 2022 | finance.yahoo.comBiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange Get BiomX News Delivered to You Automatically Sign up to receive the latest news and ratings for PHGE and its competitors with MarketBeat's FREE daily newsletter. Email Address This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry PHGE Media Mentions By Week PHGE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHGE News Sentiment▼-0.500.80▲Average Medical News Sentiment PHGE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHGE Articles This Week▼20▲PHGE Articles Average Week Get BiomX News Delivered to You Automatically Sign up to receive the latest news and ratings for PHGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ARMP News Today PLX News Today DTIL News Today ALVR News Today GRTS News Today BCAB News Today ELUT News Today ATRA News Today TIL News Today PASG News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:PHGE) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWho are Nvidia’s New Silent Partners?Weiss RatingsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin Pro Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiomX Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
